Kite Pharma (KITE) has an average broker rating of 1.33, which is interpreted as a Strong Buy, as rated by 9 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Kite Pharma (KITE) : Currently there are 8 street experts covering Kite Pharma (KITE) stock. The most bullish and bearish price target for the stock is $87 and $58 respectively for the short term. The average price target of all the analysts comes to $72.13. The estimated standard deviation from the target is $9.43.
For the current week, the company shares have a recommendation consensus of Buy.
Kite Pharma (NASDAQ:KITE): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $55.70 and $55.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $59.29. The buying momentum continued till the end and the stock did not give up its gains. It closed at $59.25, notching a gain of 5.84% for the day. The total traded volume was 781,979 . The stock had closed at $55.98 on the previous day.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.